Related Experiment Video
Updated: Jan 30, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous
Yanhua Chen1, Lajos Gera2, Shumin Zhang3
1Department of Hand Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Molecular Oncology and Biomarkers Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Abstract:
Bone metastasis is a major cause of prostate cancer (PCa) mortality. Although docetaxel chemotherapy initially extends patients' survival, in most cases PCa becomes chemoresistant and eventually progresses without a cure. In this study, we developed a novel small-molecule compound BKM1972, which exhibited potent in vitro cytotoxicity in PCa and other cancer cells regardless of their differences in chemo-responsiveness. Mechanistic studies demonstrated that BKM1972 effectively inhibited the expression of anti-apoptotic protein survivin and membrane-bound efflux pump ATP binding cassette B 1 (ABCB1, p-glycoprotein), presumably via signal transducer and activator of transcription 3 (Stat3). BKM1972 was well tolerated in mice and as a monotherapy, significantly inhibited the intraosseous growth of chemosensitive and chemoresistant PCa cells. These results indicate that BKM1972 is a promising small-molecule lead to treat PCa bone metastasis and overcome docetaxel resistance.
Insights
A new compound, BKM1972, shows promise in treating prostate cancer bone metastasis. It effectively kills cancer cells, including chemoresistant types, and inhibits tumor growth in mice.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Bone metastasis is a primary driver of prostate cancer (PCa) mortality.
- Docetaxel chemotherapy offers initial survival benefits but often leads to chemoresistance and disease progression.
- Effective treatments for advanced, chemoresistant PCa, especially bone metastases, are urgently needed.
Purpose of the Study:
- To develop and evaluate a novel small-molecule compound, BKM1972, for treating prostate cancer bone metastasis.
- To assess BKM1972's efficacy against both chemosensitive and chemoresistant PCa cells.
- To elucidate the molecular mechanisms underlying BKM1972's anti-cancer activity.
Main Methods:
- In vitro cytotoxicity assays were performed on various PCa and cancer cell lines.
- Mechanistic studies investigated the inhibition of survivin, ABCB1 (p-glycoprotein), and Stat3 signaling.
- In vivo studies evaluated BKM1972's tolerability and anti-tumor efficacy in mouse models of intraosseous PCa growth.
Main Results:
- BKM1972 demonstrated potent in vitro cytotoxicity across diverse cancer cell lines, irrespective of chemo-responsiveness.
- BKM1972 significantly inhibited survivin and ABCB1 expression, likely through Stat3 pathway modulation.
- The compound was well tolerated in mice and effectively suppressed intraosseous tumor growth in both chemosensitive and chemoresistant PCa models.
Conclusions:
- BKM1972 is a novel small-molecule inhibitor with significant anti-cancer activity against prostate cancer bone metastasis.
- BKM1972 shows potential in overcoming docetaxel resistance and warrants further development as a therapeutic agent.
Related Concept Videos
02:56Treatment Resistant Cancers
00:46Feedback Inhibition
01:23Negative Regulator Molecules
01:27Growth Models with Integration: Problem Solving
02:33Exponential Equations for Modeling Growth
02:38Molecules and Compounds